Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
- Conditions
- Glioma, MalignantGlioblastoma
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- InSightec
- Target Recruit Count
- 5
- Registration Number
- NCT04998864
- Locations
- 🇮🇹
Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy
🇪🇸CINAC-Hospital HM Puerta del Sur, Móstoles, Madrid, Spain
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
- Conditions
- Tremor Associated With Tremor Dominant Parkinson's Disease
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InSightec
- Target Recruit Count
- 50
- Registration Number
- NCT04991831
- Locations
- 🇺🇸
Miami Neuroscience Institute Baptist Health, Miami, Florida, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- InSightec
- Target Recruit Count
- 10
- Registration Number
- NCT04744493
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
- Conditions
- Parkinson Disease
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- InSightec
- Target Recruit Count
- 50
- Registration Number
- NCT04728295
- Locations
- 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸Delray Medical Center, Delray Beach, Florida, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma
- Conditions
- Glioma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InSightec
- Target Recruit Count
- 120
- Registration Number
- NCT04667715
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of MRgFUS Exablate Treatment Following the Neuropathic Pain
- Conditions
- Neuropathic Pain
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- InSightec
- Target Recruit Count
- 30
- Registration Number
- NCT04649554
- Locations
- 🇮🇹
Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
- Conditions
- Recurrent Glioblastoma
- Interventions
- Device: Exablate BBBD
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- InSightec
- Target Recruit Count
- 13
- Registration Number
- NCT04440358
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇮🇹Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy
🇰🇷Yonsei University Medical Center, Seoul, Korea, Republic of
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
- Conditions
- Recurrent Glioblastoma
- Interventions
- Device: Exablate BBBD
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- InSightec
- Target Recruit Count
- 30
- Registration Number
- NCT04417088
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- InSightec
- Target Recruit Count
- 4
- Registration Number
- NCT04370665
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD) And/or Other Substance Use Disorders (SUDs)
- Conditions
- Opioid-use DisorderSubstance Use Disorders
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- InSightec
- Target Recruit Count
- 29
- Registration Number
- NCT04197921
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸University of Maryland, Baltimore, Baltimore, Maryland, United States
🇺🇸West Virginia University: Rockefeller Neuroscience Institute, Morgantown, Virginia, United States